secwatch.observer — SEC 8-K summary
======================================

Issuer:     DBV Technologies S.A. (DBVT)
CIK:        0001613780
Form:       8-K
Filed at:   2026-06-05T20:01:38+00:00
Accession:  0001193125-26-259488
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DBV Technologies grants CEO Daniel Tassé 4.06M PSUs tied to FDA approval of Viaskin Peanut
--------------------------------------------------------------------------------

- 4,060,000 PSUs awarded to CEO; vesting conditioned on FDA approval of Viaskin Peanut BLA.
- First FDA approval of VP (any age) triggers vesting of 2,900,000 PSUs; second approval for a different indication/age triggers 1,160,000 PSUs.
- Single BLA covering both age groups deems all performance conditions satisfied.
- Vested shares delivered in four equal installments starting July 1, 2028 through January 1, 2030.
- PSUs canceled if performance conditions not met by July 1, 2028; continued employment required.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1613780/000119312526259488/0001193125-26-259488-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1613780/000119312526259488/d139789d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-259488

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer